[
  {
    "ts": null,
    "headline": "Stifel Downgrades Zoetis (ZTS) Stock, Reduces PT",
    "summary": "Zoetis Inc. (NYSE:ZTS) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, Stifel analyst Jonathan Block downgraded Zoetis Inc. (NYSE:ZTS)’s stock to “Hold” from “Buy,” reducing the price objective to $160 from $165. The firm warned that revenue growth might fall short of Wall Street expectations over the […]",
    "url": "https://finnhub.io/api/news?id=3432d7f7e98c46f5ff305435e3d46bd67c60dce3d01bb1706a38bbd4a55b9d1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750870846,
      "headline": "Stifel Downgrades Zoetis (ZTS) Stock, Reduces PT",
      "id": 135527858,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Zoetis Inc. (NYSE:ZTS) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, Stifel analyst Jonathan Block downgraded Zoetis Inc. (NYSE:ZTS)’s stock to “Hold” from “Buy,” reducing the price objective to $160 from $165. The firm warned that revenue growth might fall short of Wall Street expectations over the […]",
      "url": "https://finnhub.io/api/news?id=3432d7f7e98c46f5ff305435e3d46bd67c60dce3d01bb1706a38bbd4a55b9d1a"
    }
  },
  {
    "ts": null,
    "headline": "US CDC vaccine panel postpones vote on RSV therapies",
    "summary": "The U.S. Centers for Disease Controland Prevention's revamped vaccine advisory panel on Wednesdaypostponed its vote on the use of respiratory syncytial virustherapies to Thursday. The...",
    "url": "https://finnhub.io/api/news?id=bd43d081720cdf6deed074321fa81978547a428964ee1b91882f5f4ea81111a7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750869376,
      "headline": "US CDC vaccine panel postpones vote on RSV therapies",
      "id": 135528592,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "The U.S. Centers for Disease Controland Prevention's revamped vaccine advisory panel on Wednesdaypostponed its vote on the use of respiratory syncytial virustherapies to Thursday. The...",
      "url": "https://finnhub.io/api/news?id=bd43d081720cdf6deed074321fa81978547a428964ee1b91882f5f4ea81111a7"
    }
  },
  {
    "ts": null,
    "headline": "Will New Drugs Enable BMY to Offset the Impact of Generic Competition?",
    "summary": "BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.",
    "url": "https://finnhub.io/api/news?id=57eb58841c984a3c41f54f6ff2cb7c084852b5aa1ef3fff7d006015493d42d5f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750860120,
      "headline": "Will New Drugs Enable BMY to Offset the Impact of Generic Competition?",
      "id": 135526366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.",
      "url": "https://finnhub.io/api/news?id=57eb58841c984a3c41f54f6ff2cb7c084852b5aa1ef3fff7d006015493d42d5f"
    }
  },
  {
    "ts": null,
    "headline": "Merck Moves Past 50-Day Average: How to Play MRK Stock Now",
    "summary": "MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.",
    "url": "https://finnhub.io/api/news?id=0312544cbf19942e23fae6f0832548e1dc1bdb5c7f1fb6bc9ff99d3bc6108fb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750859940,
      "headline": "Merck Moves Past 50-Day Average: How to Play MRK Stock Now",
      "id": 135531670,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.",
      "url": "https://finnhub.io/api/news?id=0312544cbf19942e23fae6f0832548e1dc1bdb5c7f1fb6bc9ff99d3bc6108fb9"
    }
  },
  {
    "ts": null,
    "headline": "Merck : Expands Innovative Internal Generative AI Solutions Helping to Deliver Medicines to Patients Faster - Merck.com",
    "summary": "June 25, 2025 1:12 pm ET New platform utilizes advanced data engineering and LLMs to enhance clinical study report development, helping deliver medicines to patients faster ...",
    "url": "https://finnhub.io/api/news?id=483d98e7f9636e9407da8bddf4f835aabefa39ce2662712a3d095cacd28f45f2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750857786,
      "headline": "Merck : Expands Innovative Internal Generative AI Solutions Helping to Deliver Medicines to Patients Faster - Merck.com",
      "id": 135527070,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "June 25, 2025 1:12 pm ET New platform utilizes advanced data engineering and LLMs to enhance clinical study report development, helping deliver medicines to patients faster ...",
      "url": "https://finnhub.io/api/news?id=483d98e7f9636e9407da8bddf4f835aabefa39ce2662712a3d095cacd28f45f2"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade",
    "summary": "Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade",
    "url": "https://finnhub.io/api/news?id=a3823b4eab8a3b599bb3f96eadd46ece5ce0a8a1b93cde82204d858cec42fb25",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750843166,
      "headline": "Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade",
      "id": 135525019,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=a3823b4eab8a3b599bb3f96eadd46ece5ce0a8a1b93cde82204d858cec42fb25"
    }
  },
  {
    "ts": null,
    "headline": "Jefferies Maintains a Buy Rating on Merck & Co. (MRK), Keeps the PT Unchanged",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best and Cheap Stocks to Buy Now. On June 18, Akash Tewari, an analyst from Jefferies, maintained the Buy rating on Merck & Co., Inc. (NYSE:MRK) with a price target of $138. The positive outlook is based on the stability of the company’s vaccine sales and […]",
    "url": "https://finnhub.io/api/news?id=a2ce4e47d54104d72ad203d638679e147ff1b1483198947233961e0c1dd7dfa8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750840174,
      "headline": "Jefferies Maintains a Buy Rating on Merck & Co. (MRK), Keeps the PT Unchanged",
      "id": 135531672,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best and Cheap Stocks to Buy Now. On June 18, Akash Tewari, an analyst from Jefferies, maintained the Buy rating on Merck & Co., Inc. (NYSE:MRK) with a price target of $138. The positive outlook is based on the stability of the company’s vaccine sales and […]",
      "url": "https://finnhub.io/api/news?id=a2ce4e47d54104d72ad203d638679e147ff1b1483198947233961e0c1dd7dfa8"
    }
  },
  {
    "ts": null,
    "headline": "Kennedy remake of CDC vaccine panel has US insurers reassessing sources of expertise",
    "summary": "Health insurers areconsidering new expert sources to help determine which vaccinesto pay for as anti-vaccine activist and now U.S. HealthSecretary Robert F. Kennedy Jr. begins to revise...",
    "url": "https://finnhub.io/api/news?id=6455d6769917a5bdc603afa0c7c6846347f2166a477101bc4b5468595d62e2aa",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750831323,
      "headline": "Kennedy remake of CDC vaccine panel has US insurers reassessing sources of expertise",
      "id": 135523592,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Health insurers areconsidering new expert sources to help determine which vaccinesto pay for as anti-vaccine activist and now U.S. HealthSecretary Robert F. Kennedy Jr. begins to revise...",
      "url": "https://finnhub.io/api/news?id=6455d6769917a5bdc603afa0c7c6846347f2166a477101bc4b5468595d62e2aa"
    }
  },
  {
    "ts": null,
    "headline": "Kennedy's US vaccine panel set to break norms meant to ensure sound policy",
    "summary": "* Vaccine panel meeting changes raise concerns amongexperts,former members * Experts raise concerns over thimerosal presentation byanti-vaccine group member ...",
    "url": "https://finnhub.io/api/news?id=ec1fea20c65143c1cebe729836f3fe0dc210bd4f47c36f67f543a4c32cec8ae3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750831289,
      "headline": "Kennedy's US vaccine panel set to break norms meant to ensure sound policy",
      "id": 135523594,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "* Vaccine panel meeting changes raise concerns amongexperts,former members * Experts raise concerns over thimerosal presentation byanti-vaccine group member ...",
      "url": "https://finnhub.io/api/news?id=ec1fea20c65143c1cebe729836f3fe0dc210bd4f47c36f67f543a4c32cec8ae3"
    }
  },
  {
    "ts": null,
    "headline": "2 Cash-Producing Stocks for Long-Term Investors and 1 to Think Twice About",
    "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
    "url": "https://finnhub.io/api/news?id=6116583510392c13e86faef46749f71f0cbabf5b9d708221f46e3d55904e3027",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750825876,
      "headline": "2 Cash-Producing Stocks for Long-Term Investors and 1 to Think Twice About",
      "id": 135525520,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
      "url": "https://finnhub.io/api/news?id=6116583510392c13e86faef46749f71f0cbabf5b9d708221f46e3d55904e3027"
    }
  }
]